Literature DB >> 32997578

Reply to L. C. Mendez et al and M. A. Kollmeier et al.

William C Jackson1, Holly E Hartman1, Robert T Dess1, Daniel E Spratt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32997578      PMCID： PMC7655022          DOI： 10.1200/JCO.20.02422

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  11 in total

1.  Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

Authors:  Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Donald Berry; Noel Clarke; Laurence Collette; Anthony D'Amico; Richard De Abreu Lourenco; James Dignam; Mario Eisenberger; Nicholas James; Karim Fizazi; Silke Gillessen; Yohann Loriot; Nicolas Mottet; Wendy Parulekar; Howard Sandler; Daniel E Spratt; Matthew R Sydes; Bertrand Tombal; Scott Williams; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2020-06-18       Impact factor: 44.544

2.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Authors:  W James Morris; Scott Tyldesley; Sree Rodda; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-24       Impact factor: 7.038

Review 3.  What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?

Authors:  Marisa A Kollmeier; Michael J Zelefsky
Journal:  Nat Clin Pract Urol       Date:  2008-09-23

4.  Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.

Authors:  Lucas Castro Mendez; Kevin Martell; Juanita M Crook
Journal:  J Clin Oncol       Date:  2020-09-30       Impact factor: 44.544

5.  Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.

Authors:  Marisa A Kollmeier; Sean McBride; Daniel Gorovets; Michael J Zelefsky
Journal:  J Clin Oncol       Date:  2020-09-30       Impact factor: 44.544

6.  Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Authors:  Colleen A F Lawton; Xiaolei Lin; Gerald E Hanks; Herbert Lepor; David J Grignon; Harmar D Brereton; Meena Bedi; Seth A Rosenthal; Kenneth L Zeitzer; Varagur M Venkatesan; Eric M Horwitz; Thomas M Pisansky; Harold Kim; Matthew B Parliament; Rachel Rabinovitch; Mack Roach; Young Kwok; James J Dignam; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-12       Impact factor: 7.038

7.  High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Authors:  Almudena Zapatero; Araceli Guerrero; Xavier Maldonado; Ana Alvarez; Carmen Gonzalez San Segundo; Maria Angeles Cabeza Rodríguez; Victor Macias; Agustí Pedro Olive; Francesc Casas; Ana Boladeras; Carmen Martín de Vidales; Maria Luisa Vazquez de la Torre; Salvador Villà; Aitor Perez de la Haza; Felipe A Calvo
Journal:  Lancet Oncol       Date:  2015-02-19       Impact factor: 41.316

8.  Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.

Authors:  David Joseph; James W Denham; Allison Steigler; David S Lamb; Nigel A Spry; John Stanley; Tom Shannon; Gillian Duchesne; Chris Atkinson; John H L Matthews; Sandra Turner; Lizbeth Kenny; David Christie; Keen-Hun Tai; Nirdosh Kumar Gogna; Rachel Kearvell; Judy Murray; Martin A Ebert; Annette Haworth; Brett Delahunt; Christopher Oldmeadow; John Attia
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-03-15       Impact factor: 7.038

9.  Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Authors:  Michel Bolla; Philippe Maingon; Christian Carrie; Salvador Villa; Petros Kitsios; Philip M P Poortmans; Santhanam Sundar; Elzbieta M van der Steen-Banasik; John Armstrong; Jean-François Bosset; Fernanda G Herrera; Bradley Pieters; Annerie Slot; Amit Bahl; Rahamim Ben-Yosef; Dirk Boehmer; Christopher Scrase; Laurette Renard; Emad Shash; Corneel Coens; Alphonsus C M van den Bergh; Laurence Collette
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

10.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Authors:  Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Noel W Clarke; Laurence Collette; James J Dignam; Karim Fizazi; Wendy R Paruleker; Howard M Sandler; Matthew R Sydes; Bertrand Tombal; Scott G Williams; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2017-08-10       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.